| Variable | Sexual dysfunction n = 52 | No sexual dysfunction n = 55 | OR (95% CI) |
| Patient factors |
|
|
|
| Pre menopausal | 30.8% | 12.7% | 3.05 (1.14 - 9.18) |
| Age < 50 | 30.8% | 12.7% | 5.10 (1.85 - 14.10) |
| BMI > 30 | 28% | 24.5% | 1.20 (0.50 - 2.89) |
| Disease factors° |
|
|
|
| Primary disease | 72.2% | 55.6% | 2.18 (0.88 - 5.41) |
| Active disease | 50.0% | 51.0% | 0.96 (0.43 - 2.13) |
| Low stage (I/II) | 48.0% | 22.6% | 3.22 (1.35 - 7.65) |
| Recurrent disease | 26.8% | 44.4% | 1.0 |
| Disease site |
|
|
|
| Cervical cancer | 25.0% | 9.1% | 4.49 (1.26 - 16.0) |
| Ovarian cancer | 51.9% | 47.3% | 1.79 (0.72 - 4.45) |
| Uterine cancer | 21.2% | 34.5% | 1.0 |
| Treatment factors |
|
|
|
| Chemotherapy | 74.3% | 25.7% | 2.42 (1.24 - 4.69) |
| Chemo + surgery | 44.0% | 34.0% | 0.11 (0.01 - 2.30) |
| Chemo + radiation | 55.0% | 45.0% | 0.17 (0.01 - 4.03) |
| Chemo + surgery + radiation | 59.0% | 41.0% | 0.20 (0.01 - 4.07) |
| Chemotherapy details§ |
|
|
|
| Carboplatinum | 69.2% | 72.7% | 0.84 (0.37 - 1.95) |
| Cisplatin | 46.2% | 32.7% | 1.76 (0.80 - 1.95) |
| Paclitaxel | 69.2% | 72.7% | 0.84 (0.37 - 1.95) |
| >6 cycles chemotherapy | 33.3% | 36.4% | 0.58 (0.25 - 1.34) |
| >1 chemotherapy regimen | 25.5% | 39.6% | 0.52 (0.23 - 1.20) |